Accès à distance ? S'identifier sur le proxy UCLouvain
Novel products for haemostasis
Primary tabs
Document type | Article de périodique (Journal article) – Synthèse de littérature |
---|---|
Access type | Accès restreint |
Publication date | 2014 |
Language | Anglais |
Journal information | "Haemophilia" - Vol. 20, no. S4, p. 29-35 (2014) |
Peer reviewed | yes |
Publisher | Wiley-Blackwell Publishing Ltd. ((United Kingdom) Oxford) |
issn | 1351-8216 |
e-issn | 1365-2516 |
Publication status | Publié |
Affiliations |
UCL
- SSS/IREC/CARD - Pôle de recherche cardiovasculaire UCL - (SLuc) Service d'hématologie UCL - (SLuc) Centre de malformations vasculaires congénitales |
Links |
- Kitazawa Takehisa, Igawa Tomoyuki, Sampei Zenjiro, Muto Atsushi, Kojima Tetsuo, Soeda Tetsuhiro, Yoshihashi Kazutaka, Okuyama-Nishida Yukiko, Saito Hiroyuki, Tsunoda Hiroyuki, Suzuki Tsukasa, Adachi Hideki, Miyazaki Taro, Ishii Shinya, Kamata-Sakurai Mika, Iida Takeo, Harada Aya, Esaki Keiko, Funaki Miho, Moriyama Chifumi, Tanaka Eriko, Kikuchi Yasufumi, Wakabayashi Tetsuya, Wada Manabu, Goto Masaaki, Toyoda Takeshi, Ueyama Atsunori, Suzuki Sachiyo, Haraya Kenta, Tachibana Tatsuhiko, Kawabe Yoshiki, Shima Midori, Yoshioka Akira, Hattori Kunihiro, A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model, 10.1038/nm.2942
- Sampei Zenjiro, Igawa Tomoyuki, Soeda Tetsuhiro, Okuyama-Nishida Yukiko, Moriyama Chifumi, Wakabayashi Tetsuya, Tanaka Eriko, Muto Atsushi, Kojima Tetsuo, Kitazawa Takehisa, Yoshihashi Kazutaka, Harada Aya, Funaki Miho, Haraya Kenta, Tachibana Tatsuhiko, Suzuki Sachiyo, Esaki Keiko, Nabuchi Yoshiaki, Hattori Kunihiro, Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity, 10.1371/journal.pone.0057479
- Muto A., Yoshihashi K., Takeda M., Kitazawa T., Soeda T., Igawa T., Sakamoto Y., Haraya K., Kawabe Y., Shima M., Yoshioka A., Hattori K., Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation, 10.1111/jth.12474
- Tomokiyo K., Nakatomi Y., Araki T., Teshima K., Nakano H., Nakagaki T., Miyamoto S., Funatsu A., Iwanaga S., A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone, 10.1111/j.0042-9007.2003.00365.x
- Nakatomi Yasushi, Nakashima Teruhisa, Gokudan Soutaro, Miyazaki Hiroki, Tsuji Manami, Hanada-Dateki Takako, Araki Tatsuya, Tomokiyo Kazuhiko, Hamamoto Takayoshi, Ogata Yoichi, Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent, 10.1016/j.thromres.2009.12.010
- SHIRAHATA A., FUKUTAKE K., MIMAYA J., TAKAMATSU J., SHIMA M., HANABUSA H., TAKEDANI H., TAKASHIMA Y., MATSUSHITA T., TAWA A., HIGASA S., TAKATA N., SAKAI M., KAWAKAMI K., OHASHI Y., SAITO H., Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - Phase I trial : PHARMACOLOGICAL STUDY OF A FACTOR VIIA AND X MIXTURE, 10.1111/j.1365-2516.2011.02548.x
- Shirahata A., Fukutake K., Mimaya J., Takamatsu J., Shima M., Hanabusa H., Takedani H., Takashima Y., Matsushita T., Tawa A., Higasa S., Takata N., Sakai M., Kawakami K., Ohashi Y., Saito H., Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors-phase I trial: 2nd report, 10.1111/hae.12024
- Shirahata A., Fukutake K., Takamatsu J., Shima M., Hanabusa H., Mugishima H., Amano K., Takedani H., Tamashima S., Matsushita T., Tawa A., Tanaka I., Higasa S., Kosaka Y., Fujii T., Sakai M., Migita M., Kawakami K., Ohashi Y., Saito H., A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics, 10.1111/hae.12205
- Berntorp Erik, Shapiro Amy D, Modern haemophilia care, 10.1016/s0140-6736(11)61139-2
- Orlova, Acta Naturae, 5, 19 (2013)
- Mannucci P. M., Mancuso M. E., Santagostino E., How we choose factor VIII to treat hemophilia, 10.1182/blood-2012-01-394411
- Farfan-Portet María-Isabel, Gerkens Sophie, Lepage-Nefkens Isabelle, Vinck Irmgard, Hulstaert Frank, Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?, 10.1007/s10198-013-0538-4
- Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use 2013
- Abraham Jame, Introduction and Commentary: Paving the Way for Biosimilars in Oncology, 10.1053/j.seminoncol.2013.09.014
- Dranitsaris George, Amir Eitan, Dorward Kristine, Biosimilars of Biological Drug Therapies : Regulatory, Clinical and Commercial Considerations, 10.2165/11593730-000000000-00000
- Mellstedt H., Niederwieser D., Ludwig H., The challenge of biosimilars, 10.1093/annonc/mdm345
- Kaufman R. J., Powell J. S., Molecular approaches for improved clotting factors for hemophilia, 10.1182/blood-2013-07-498261
- Hay C. R. M., Purchasing factor concentrates in the 21st century through competitive tendering, 10.1111/hae.12169
- El-Ekiaby, Haemophilia, 17, e884 (2011)
- Brooker M Registry of clotting factor concentrates Facts and Figures http://www1.wfh.org/publication/files/pdf-1227.pdf
- Casini Alessandro, Neerman-Arbez Marguerite, de Moerloose Philippe, Congenital Fibrinogen Disorders: An Update, 10.1055/s-0033-1349222
- RADULOVIC V., BAGHAEI F., BLIXTER I. Fagerberg, SAMUELSSON S., JEPPSSON A., Comparable effect of recombinant and plasma-derived human fibrinogen concentrate on ex vivo clot formation after cardiac surgery : Letter to the Editor, 10.1111/j.1538-7836.2012.04823.x
- Lancellotti Stefano, Basso Maria, De Cristofaro Raimondo, Congenital Prothrombin Deficiency: An Update, 10.1055/s-0033-1348948
- Escobar M. A., Advances in the treatment of inherited coagulation disorders, 10.1111/hae.12137
- Boehlen Françoise, Casini Alessandro, Pugin François, de Moerloose Philippe, Pulmonary embolism and fatal stroke in a patient with severe factor XI deficiency after bariatric surgery : , 10.1097/mbc.0b013e32835bdbec
- Duga Stefano, Salomon Ophira, Congenital Factor XI Deficiency: An Update, 10.1055/s-0033-1353420
- Inbal A., Oldenburg J., Carcao M., Rosholm A., Tehranchi R., Nugent D., Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency, 10.1182/blood-2011-10-386045
- Peyvandi F., Garagiola I., Seregni S., Future of coagulation factor replacement therapy, 10.1111/jth.12270
Bibliographic reference | Shima, Midori ; Hermans, Cédric ; de Moerloose, Phiłippe. Novel products for haemostasis. In: Haemophilia, Vol. 20, no. S4, p. 29-35 (2014) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/164239 |